vTv Therapeutics Secures $20M Non-Dilutive Funding, Updates Phase 3 Trial, and Reports Q4/FY25 Results

summarizeSummary

vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a $20.0 million non-dilutive upfront payment from an amended licensing agreement and an update on its Phase 3 CATT1 trial for cadisegliatin.

check_boxKey Events

• Secured $20.0 Million Non-Dilutive Funding

  Received an upfront payment of $20.0 million in February 2026 from Newsoara Biopharma Inc. under an amended licensing agreement for global rights to HPP737, with potential for up to $115.0 million in future milestones and tiered royalties.

• Strengthened Balance Sheet and Extended Runway

  Cash and cash equivalents increased to $88.9 million as of December 31, 2025, from $36.7 million in 2024, with the new funding extending the runway well past the CATT1 Phase 3 topline readout.

• Phase 3 CATT1 Trial Enrollment Update

  Expects to complete enrollment in the CATT1 Phase 3 trial for cadisegliatin in Type 1 Diabetes in the third quarter of 2026, following an acceleration in enrollment momentum despite initial delays.

• Expanded Cadisegliatin Development into Type 2 Diabetes

  Submitted a Phase 2 clinical study protocol for cadisegliatin in Type 2 Diabetes to the UAE Department of Health in December 2025, broadening the drug's potential market.

auto_awesomeAnalysis

vTv Therapeutics announced a significant non-dilutive funding event, securing $20.0 million upfront from an amended licensing agreement with Newsoara for global rights to its PDE4 inhibitor, HPP737. This substantial cash infusion, representing approximately 13.7% of the company's market capitalization, significantly strengthens the balance sheet and extends the funding runway well past the anticipated Phase 3 topline readout for cadisegliatin. While the company reported an increased net loss for the full year 2025, the improved cash position and strategic licensing deal provide critical capital for ongoing clinical development. The update on the CATT1 Phase 3 trial, despite initial enrollment delays, provides a clear timeline for completion in Q3 2026, and the expansion of cadisegliatin into a Phase 2 study for Type 2 Diabetes opens new market potential.